Trials / Conditions / Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

20 registered clinical trials studyying Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice NCT07395804	Bayer	—
Recruiting	TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide NCT07190300	Novartis Pharmaceuticals	Phase 1 / Phase 2
Recruiting	A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer NCT07241416	Jiangsu HengRui Medicine Co., Ltd.	Phase 3
Not Yet Recruiting	CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostat NCT07268794	Fudan University	Phase 2
Recruiting	Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer NCT07216248	University of Utah	Phase 2
Recruiting	Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Canc NCT07181122	Ankara Etlik City Hospital	—
Recruiting	Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor P NCT07140900	Amgen	Phase 1
Withdrawn	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alter NCT06392841	Qian Qin	Phase 2
Recruiting	A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation NCT06661122	Bayer	—
Active Not Recruiting	PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer NCT06479187	Brigham and Women's Hospital	Phase 4
Completed	Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostat NCT06312670	Pedro Barata, MD, MSc	Phase 2
Recruiting	PROCARE - PROstate Cancer Real World Evidence Registry NCT06835218	UroTrials Company (GmbH)	—
Active Not Recruiting	A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastat NCT06010914	Bayer	—
Active Not Recruiting	Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients NCT06019676	Royal Marsden NHS Foundation Trust	—
Recruiting	Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC NCT05956639	The First Affiliated Hospital with Nanjing Medical University	Phase 3
Active Not Recruiting	A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + AD NCT05676203	Jena University Hospital	Phase 3
Recruiting	Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment NCT05649943	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	N/A
Active Not Recruiting	Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression NCT05683964	Beth Israel Deaconess Medical Center	EARLY_Phase 1
Completed	The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC NCT03899467	Suzhou Kintor Pharmaceutical Inc,	Phase 2
Recruiting	ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer NCT03903835	Karolinska Institutet	Phase 3